Aethlon Medical (NASDAQ:AEMD) Earns Sell Rating from Analysts at StockNews.com

Posted by on Apr 26th, 2023

Investment analysts at StockNews.com began coverage on shares of Aethlon Medical (NASDAQ:AEMD – Get Rating) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the medical equipment provider’s stock.

Aethlon Medical Stock Performance

Shares of AEMD opened at $0.45 on Wednesday. The stock has a 50 day moving average price of $0.44 and a two-hundred day moving average price of $0.45. The firm has a market capitalization of $10.34 million, a P/E ratio of -0.61 and a beta of 1.17. Aethlon Medical has a 52 week low of $0.23 and a 52 week high of $2.46.

Aethlon Medical (NASDAQ:AEMD – Get Rating) last announced its earnings results on Monday, February 13th. The medical equipment provider reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.08). On average, equities analysts forecast that Aethlon Medical will post -0.64 earnings per share for the current year.

Hedge Funds Weigh In On Aethlon Medical

Several institutional investors have recently bought and sold shares of AEMD. HRT Financial LP purchased a new position in Aethlon Medical in the fourth quarter valued at approximately $28,000. Renaissance Technologies LLC lifted its stake in Aethlon Medical by 61.4% in the fourth quarter. Renaissance Technologies LLC now owns 100,600 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 38,264 shares during the last quarter. Buckingham Strategic Partners purchased a new position in Aethlon Medical in the third quarter valued at approximately $29,000. Two Sigma Investments LP purchased a new position in Aethlon Medical in the third quarter valued at approximately $32,000. Finally, Jane Street Group LLC lifted its stake in Aethlon Medical by 895.7% in the fourth quarter. Jane Street Group LLC now owns 140,245 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 126,160 shares during the last quarter. Hedge funds and other institutional investors own 11.86% of the company’s stock.

Aethlon Medical Company Profile

(Get Rating)

Aethlon Medical, Inc is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. It develops Aethlon Hemopurifier, which is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The firm operates through the following segments: Aethlon and ESI.

See Also

Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.